Articles

Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis

Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center;Sackler School of Medicine, Tel Aviv University, Israel
Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center;Sackler School of Medicine, Tel Aviv University, Israel
Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center;Sackler School of Medicine, Tel Aviv University, Israel
Internal Medicine Department A, Meir Hospital
Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center;Sackler School of Medicine, Tel Aviv University, Israel
Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center;Sackler School of Medicine, Tel Aviv University, Israel
Infectious Disease Unit, Rabin Medical Center;Sackler School of Medicine, Tel Aviv University, Israel
Sackler School of Medicine, Tel Aviv University, Israel
Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center;Sackler School of Medicine, Tel Aviv University, Israel
Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center;Sackler School of Medicine, Tel Aviv University, Israel
Vol. 98 No. 1 (2013): January, 2013 https://doi.org/10.3324/haematol.2012.063172